Among patients with PD-1/PD-L1-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), treatment with ...

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients[i] New findings from this investigational study build on the strength of the data for amivantamab in ...